Drug intelligence / Profile preview

CpG oligonucleotide + HER2-targeted therapy

Development stage: Preclinical
Lead developer: Changchun Huapu Biotechnology
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

CpG oligonucleotide + HER2-targeted therapy is a combination immunotherapy being developed by Huapu Biotechnology for the treatment of HER2-positive tumors. The combination consists of a proprietary CpG oligodeoxynucleotide, which acts as a Toll-like receptor 9 (TLR9) agonist, and a HER2-targeted therapeutic agent. The CpG component, likely based on Huapu's proprietary HP007 technology, is designed to activate innate immunity and induce a Th1-type immune response, thereby enhancing the anti-tumor efficacy of the HER2-targeted therapy. This synergistic approach aims to overcome resistance and improve clinical outcomes in patients with HER2-expressing malignancies by leveraging both targeted inhibition and immune stimulation. The program is currently in the preclinical stage of development.

Other names: HER2-CpG oligonucleotide (TLR9 agonist)-HER2-targeted therapy (combination)

Targets

TLR9 (Toll-like receptor 9)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CpG oligonucleotide + HER2-targeted therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CpG oligonucleotide + HER2-targeted therapy.

Explore the full profile